nach oben

Erschienen in:

2014 | OriginalPaper | Buchkapitel

71. Design and Synthesis of 2-Arylbenzimidazole Analogues as Novel SIRT1 Activators for the Treatment of Type II Diabetes

verfasst von : Fei Hu, Yuanmou Chen, Yinghao Gao, Shaolong Jia, Weizhu Liu, Peng Yu, Erbing Hua

Erschienen in: Proceedings of the 2012 International Conference on Applied Biotechnology (ICAB 2012)

Verlag: Springer Berlin Heidelberg

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

SIRT1, an NAD⁺-dependent sirtuin deacetylase, has emerged as potential therapeutic target for treatment of human illnesses such as type II diabetes, cancer, cardiovascular and neurodegenerative diseases. Resveratrol, a naturally occurring small molecule activator of SIRT1, has been demonstrated to improve metabolism and glucose tolerance. SRT1720, an imidazothiazole derivative, recently made as the most potent SIRT1 activator is structurally unrelated to resveratrol. In this work, we design and synthesize a series of compounds as novel potential SIRT1 activators through a two-step convenient synthetic procedure. Fourteen 2-Arylbenzimidazole analogues were characterized on the basis of ¹H NMR spectra. Tests for biological activity of these compounds are underway.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel A New Process for Preparation of Hydroxytyrosol

Nächstes Kapitel Design and Synthesis of SRT1 Activators for Potential Lead Compounds of Treatment of Diabetes

Dekker JM, Girman C, Gieln R, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ (2005) Metabolic syndrome and 10-year cardiovascular disease risk in the hoorn study. Epidemiology 112:666–673

Russo A, Autelitano M, Bisanti L (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44(2):293–7

Guarente Leonard (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444:868–874CrossRef

Rodgers, JT Carlos Lerin, Wilhelm Haas, Steven P Gygi Bruce. M,Spiegelman. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434:113-118

Bordone L, Motta MC, Picard F, Robinson A, Ulupi SJ, Apfeld J (2006) Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 4(2):e31

Moynihan KA, Grimm AA, Bernal-Mizrachi E, Plueger MM, Ford E, Cras-Méneur C, Permutt MA, Imai S (2005) Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab Aug; 2(2):105–17

Picard F, Kurtev M, Chung N et al (2004) SIRT1 promotes fat mobilization in white adipocytes by repressing PPAR-γ Nature 429:771–776CrossRef

Brunet A et al (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:2011–2015CrossRef

Luo J et al (2001) Negative control of p53 by Sir2a promotes cell survival under stress. Cell 107:137–148CrossRef

10.

Motta MC et al (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116:551–563CrossRef

11.

Vaziri H et al (2001) hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149–159CrossRef

12.

Wang C et al (2006) Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 8:1025–1031CrossRef

13.

Chen D et al (2005) Increase in activity during calorie restriction requires Sirt1. Science 310:1641CrossRef

14.

Cohen HY et al (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305:390–392CrossRef

15.

Bordone L, Guarente L (2005) Calorie restriction, SIRT1 and metabolism: understanding longevity. Nature Rev Mol Cell Biol 6:298–305CrossRef

16.

Barzilai N, Banerjee S, Hawkins M, Chen W, Rossetti L (1998) Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. J Clin Invest 101:1353–1361CrossRef

17.

Smith JJ, Gagne DJ, Galonek HL (2009) Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol 3:31CrossRef

18.

Baur JA et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342CrossRef

19.

Wood JG et al (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430:686–689CrossRef

20.

Milne JC, Philip D, Lambert, David P, Carney et al (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 29 450(7170):712–6

21.

Tebbe MJ, Spitzer WA, F Victor S.C. Miller CC, Lee TR, Sattelberg E, Mckinney, Tang CJ (1997) Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice. J Med Chem 40 (24):3937–3946

22.

Porcari AR, Devivar RV, Kucera LS, Drach JC, Townsend LB (1998) Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)-2-substituted-5, 6-dichloro-benzimidazoles as nonnucleoside analogues of 2, 5, 6-trichloro1- ((-d-ribofuranosyl)benzimidazole. J Med Chem 41:1251CrossRef

23.

Roth M, Morningstar ML, Boyer PL, Hughes SH, Bukheit RW, Michejda CJ (1997) Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-Substituted Benzimidazoles. J Med Chem40(26): 4199–4207

24.

Migawa MT, Giradet JL, Walker JA, Koszalka GW, Chamber-Lain SD, Drach JC, Townsend LB (1998) Design, synthesis, and antiviral activity of α-Nucleosides: D- and L-Isomers of Lyxofuranosyl- and (5-Deoxylyxofuranosyl) benzimidazoles. J Med Chem 41(8):1242–1251CrossRef

25.

Nadaf RN, Siddiqui SA, Daniel T, Lahoti RJ, Srinivasan KV (2004) Room temperature ionic liquid promoted regioselective synthesis of 2-arylbenzimidazoles, benzoxazoles and benzthiazoles under ambient conditions. J Mol Catal A: Chem 214:155CrossRef

26.

Denny WA, Rewcastle GW, Baguley BC (1990) Structure-activity relationships for 2-phenylbenzimidazole-4-carbo-xamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II. J Med Chem 33(2):814–819CrossRef

27.

Forseca T, Gigante B, Gilchrist TL (2001) A short synthesis of phenanthro[2,3-d]imidazoles from dehydroabietic acid. Application of the methodology as a convenient route to benzimidazoles. Tetrahedron 57(9):1793–1799

Titel: Design and Synthesis of 2-Arylbenzimidazole Analogues as Novel SIRT1 Activators for the Treatment of Type II Diabetes
verfasst von: Fei Hu
Yuanmou Chen
Yinghao Gao
Shaolong Jia
Weizhu Liu
Peng Yu
Erbing Hua
Verlag: Springer Berlin Heidelberg
Buch: Proceedings of the 2012 International Conference on Applied Biotechnology (ICAB 2012)
Print ISBN: 978-3-642-37921-5

Electronic ISBN: 978-3-642-37922-2

Copyright-Jahr: 2014
DOI: https://doi.org/10.1007/978-3-642-37922-2_71

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht